Search

Vaxart Inc

Închisă

0

Rezumat

Modificarea prețului

24h

Curent

Minim

Maxim

Indicatori cheie

By Trading Economics

Venit

-19M

-13M

Vânzări

-12M

27M

P/E

Medie Sector

2.882

55.725

EPS

-0.06

Marjă de profit

-49.638

Angajați

65

EBITDA

-19M

-12M

Dividende

By Acuity

Următoarele câștiguri

12 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-24M

119M

Deschiderea anterioară

0

Închiderea anterioară

0

Vaxart Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 sept. 2026, 23:31 UTC

S&P Global Manufacturing PMI for South Korea set to release on October 1, 2026, amid cautious market expectations influenced by rising energy prices and geopolitical tensions.

26 sept. 2026, 23:31 UTC

S&P/Case-Shiller Home Price Index Set for Release with Anticipated 2.2% Growth Amid Mixed Market Sentiment and Economic Pressures

26 sept. 2026, 23:31 UTC

Brazil's Industrial Production MoM data release on October 2, 2026, expected to show growth trends amid recent fluctuations.

26 sept. 2026, 23:22 UTC

U.S. Q2 GDP Growth Rate Forecasted at +1.6% Amid Economic Concerns and Market Volatility Ahead of September 30 Release

26 sept. 2026, 23:22 UTC

Upcoming PCE Price Index release on September 30 raises inflation concerns amid rising commodity prices and geopolitical tensions.

26 sept. 2026, 23:22 UTC

U.S. Personal Spending Expected to Rise 0.8% in August Amid Caution Over Inflation and Consumer Confidence Decline

26 sept. 2026, 23:22 UTC

Upcoming U.S. Retail Inventories Ex Autos Report on September 30 Expected to Reflect Consumer Demand Amid Mixed Economic Signals.

26 sept. 2026, 23:22 UTC

U.S. Goods Trade Balance Report Set for Release Amid Anticipated $108.5 Billion Deficit and Positive Tariff Negotiations with China

26 sept. 2026, 23:22 UTC

US Personal Income Expected to Rise 0.4% in August Amid Economic Recovery and Inflation Concerns

26 sept. 2026, 23:22 UTC

U.S. Wholesale Inventories Expected to Rise 1.1% Amid Mixed Investor Sentiment and Inflation Concerns Ahead of September Release

26 sept. 2026, 23:22 UTC

U.S. GDP Price Index Expected to Rise 0.064% Amid Mixed Economic Sentiment and Inflation Concerns Ahead of September Release

26 sept. 2026, 23:22 UTC

Core PCE Price Index MoM for August 2026 set to release on September 30, with a forecasted increase of 0.3%, amid cautious investor sentiment and rising treasury yields impacting Fed policy outlook.

26 sept. 2026, 23:22 UTC

U.S. PCE Price Index Release on September 30 Expected to Show 0.4% Monthly Increase Amid Inflation Concerns and Market Volatility

26 sept. 2026, 23:11 UTC

Cautious Market Anticipates 70,000 Job Increase in Upcoming ADP Employment Report Amid Recent Underperformance

26 sept. 2026, 23:11 UTC

Mexican Business Confidence Remains Cautious Ahead of October EMOE Release Amid U.S. Economic Concerns

26 sept. 2026, 23:11 UTC

Correlated Moves

Avalanche is trading higher, continuing its upward trend since Friday, while Ethereum remains little changed amid broader market support from easing oil prices and Treasury yields.

26 sept. 2026, 23:01 UTC

Canada's Preliminary Monthly GDP Release on September 29 Expected to Show Stability Amid Economic Challenges and Trade Tensions.

26 sept. 2026, 23:01 UTC

South Korea's October 1 export report expected to show continued strong growth, following August's impressive 68.7% surge driven by memory chip demand.

26 sept. 2026, 22:51 UTC

Japan's unemployment rate forecasted to drop slightly to 2.4% in August, amid cautious market optimism and concerns over currency depreciation and rising interest rates ahead of the October release.

26 sept. 2026, 22:51 UTC

South Africa's Balance of Trade report on September 30, 2026, expected to show continued trade surplus amid cautious optimism in exports and declining imports.

26 sept. 2026, 22:51 UTC

Germany's Inflation Rate Release on September 30, 2026: Consumer Confidence Declines Amid Rising Energy Prices and Economic Uncertainty.

26 sept. 2026, 22:51 UTC

Japan's Tankan Index Set for Positive Release Amid Cautious Market Optimism and Global Economic Pressures

26 sept. 2026, 22:51 UTC

Germany's Inflation Rate Expected to Rise 0.5% Amid Declining Consumer Confidence Due to Soaring Energy Prices

26 sept. 2026, 22:51 UTC

Macro News

The Russell 2000 Index is trading lower in after-hours, reflecting a slight decline since Friday's close, amid rising delinquency rates in the commercial real estate sector.

26 sept. 2026, 22:51 UTC

Macro News

The Dow Jones Index is lower in after-market trading, amid trade tariff discussions and rising delinquency rates in commercial real estate.

26 sept. 2026, 22:51 UTC

Macro News

The FTSE 100 Index has advanced modestly in after-market hours, following a U.S.-China tariff agreement on $30 billion in goods.

26 sept. 2026, 22:41 UTC

MBA 30-Year Mortgage Rate Hits 7.12%, Highest Since May, Amid Rising Treasury Yields and Inflation Concerns

26 sept. 2026, 22:40 UTC

Macro News

The DAX 30 Index is trading modestly lower in after-market hours, continuing its downward trend amid ongoing macroeconomic concerns and trade developments.

26 sept. 2026, 22:31 UTC

Japan's Industrial Production Expected to Rise 1.7% in August Amidst Cautious Optimism and Global Uncertainties

26 sept. 2026, 22:31 UTC

Japan's Retail Sales YoY data for August expected to rise 3.3% amid cautious optimism and inflation concerns, with market focus on currency valuation and global trends.

Comparație

Modificare preț

Vaxart Inc Așteptări

Consens privind evaluarea

By TipRanks

0 ratings

0

Cumpărare

0

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.